Download Powerpoint - Blood Journal

BCR-ABL kinase domain mutation analysis in chronic
myeloid leukemia patients treated with tyrosine kinase
inhibitors: recommendations from an expert panel on
behalf of European LeukemiaNet
by Simona Soverini, Andreas Hochhaus, Franck E. Nicolini, Franz Gruber, Thoralf
Lange, Giuseppe Saglio, Fabrizio Pane, Martin C. Müller, Thomas Ernst,
Gianantonio Rosti, Kimmo Porkka, Michele Baccarani, Nicholas C. P. Cross, and
Giovanni Martinelli
Blood
Volume 118(5):1208-1215
August 4, 2011
©2011 by American Society of Hematology
Map of all the amino acid substitutions in the Bcr-Abl KD identified in clinical samples from
patients reported to be resistant to imatinib in published papers.
Simona Soverini et al. Blood 2011;118:1208-1215
©2011 by American Society of Hematology
Flow chart summarizing when mutation analysis is recommended in CML patients treated with
imatinib first-line.
Simona Soverini et al. Blood 2011;118:1208-1215
©2011 by American Society of Hematology
Cellular IC50 (nM) of imatinib (IM), nilotinib (NI), and dasatinib (DA) and fold increase with
respect to the IC50 for wild-type (WT) Bcr-Abl of the M244V, L248V, G250E, Q252H, Y253H, Y253F,
E255K, E255V, E279K, and V299L mutant forms.
Simona Soverini et al. Blood 2011;118:1208-1215
©2011 by American Society of Hematology
Cellular IC50 (nM) of imatinib (IM), nilotinib (NI), and dasatinib (DA) and fold increase with
respect to the IC50 for wild-type (WT) Bcr-Abl of the F311L, T315I, F317L, M351T, F359V, V379I,
L384M, L387M, H396R, H396P, and F486S mutant forms.
Simona Soverini et al. Blood 2011;118:1208-1215
©2011 by American Society of Hematology